H.C. Wainwright lowered the firm’s price target on Apollomics to $2 from $5 and keeps a Buy rating on the shares after uproleselan missed the primary endpoint in Phase 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLM:
- Apollomics announces approval of vebreltinib in China
- Apollomics presents vebreltinib data at AACR meeting
- Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apollomics price target lowered to $5 from $17 at H.C. Wainwright
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results